Session 7 – Cell & Gene Therapies Date: 26 July (Friday) 9:00 – 12:00 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom A
Chien-Tsun Kuan, Ph.D.
EVP / COO & CTO
GenomeFrontier Therapeutics, Inc.
Dr. Kuan is EVP/COO & CTO of GenomeFrontier Therapeutics, a discovery to clinical stage company developing non-viral based CAR-T cell therapies for the treatment of cancer, focusing on solid tumors. In this role he is responsible for guiding the research and development of the company’s pipeline assets as well as the business operation. Prior to his current position, Dr. Kuan was Deputy Executive Director of Institute of Biologics at Development Center for Biotechnology in Taipei, Taiwan, where he lead research and development of therapeutic antibodies, protein fusions, and cellular gene therapy for the treatment of cancer, autoimmune, neurodegenerative and infectious diseases. Earlier, Dr. Kuan was a professor at Duke University Medical Center, leading the Antibody Engineering and Antibody Therapeutics Program in the Preston Robert Tisch Brain Tumor Center at Duke to translate the laboratory results to clinical trials in cancer patients.
Dr. Kuan is an immunologist and molecular biologist with more than 25 years of experience in developing antibody-based agents for the treatment and detection of cancer. He received a Ph.D. degree in Biological Sciences from Purdue University and received postdoctoral training with Dr. Ira Pastan at the NCI in USA. He holds more than 25 U.S. or international patents, and is a recipient of numerous awards including the 2014 AACR Team Science Award, and an author of more than 45 peer-reviewed published research articles and numerous scientific presentations at national or international conferences in the areas of monoclonal antibodies, recombinant immunotoxins, bispecific antibodies, and CAR-T cell therapy for cancer treatment.